The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2019 | Predictors of early relapse in transplant-eligible MM patients
Francesca Gay
• 7 Dec 2019
Francesca Gay, MD, PhD, University of Turin, Turin, Italy, discusses the integrative analysis of baseline prognostic features and achievement of measurable residual disease (MRD) negativity in an attempt to identify the main predictors of early relapse in transplant-eligible multiple myeloma (MM) patients. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
